Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance
暂无分享,去创建一个
C. Leen | C. Fraser | E. Volz | D. Pillay | R. Gilson | A. Winston | C. Sabin | F. Lampe | M. Youle | Mark Hopkins | P. Cane | J. Weber | J. Ainsworth | A. Leigh-Brown | A. Tostevin | M. Gompels | L. Campbell | F. Ibrahim | F. Post | S. Collins | M. Nelson | N. Perry | I. Williams | A. Schwenk | T. Mbisa | A. Pozniak | A. Geretti | A. Babiker | D. Chadwick | Kirsty Baillie | A. Lewszuk | E. Nastouli | O. Stirrup | E. Fearnhill | D. Dunn | S. O'shea | K. Porter | D. Churchill | P. Hay | S. Mandalia | Colette Smith | K. Templeton | E. Smit | A. Palfreeman | C. Atkinson | J. Walsh | S. Hué | V. Delpech | R. Gunson | A. Garcia-Diaz | C. Booth | C. Murphy | D. Asboe | A. Thornton | C. Wood | T. Hill | B. Gazzard | A. Hale | E. Youssef | A. Phillips | S. Dustan | D. Mital | F. Ramzan | A. Ustianowski | C. Chaloner | A. Wilson | N. Mackie | Hongyi Zhang | J. Hand | L. Lazarus | P. Tilston | J. Mullen | R. Tandy | Tracy Fawcett | B. Payne | S. Kirk | E. White | S. Kegg | S. Jose | S. Huntington | N. Brima | A. Bradley-Stewart | S. Hutchinson | Shaadi Shidfar | S. Douthwaite | R. Trevelion | S. Morris | S. Mitchell | Julie Allen | J. Dawkins | M. Carder | L. Schmid | S. Allan | J. Pritchard | A. Tariq | A. Glabay | S. Tilbury | Z. Gleisner | R. Tsintas | N. Mackie | J. Lynch | C. de Souza | S. Munshi | Sue Allan | S. Russell-Sharpe | A. Harte | H. Spencer | Ron Jones | S. Cumming | J. Hubb | C. Orkin | L. Renwick | Victoria Ogunbiyi | S. Miller | David T. Dunn | Margaret A. Johnson | C. Taylor | Tracey Mabika | Ade Adefisan | Akin Faleye | Christian Kemble | Janet Gravely | Veronica Edgell | Ilise Gunder | D. Clark | Anna Tostevin | David Anton Patricia David Duncan Duncan Simon Valerie S Asboe Pozniak Cane Chadwick Churchill Clark | F. Martin | Jane Anderson | Peter Tilston | Maria Anna Geretti | Jonathan Sris Jane Abdel David Duncan Valerie David Brian R Ainsworth Allan Anderson Babiker Chadwic | A. Sabin | S. Russell‐Sharpe | Jonathan Hubb | Brendan A. I. Payne | Oliver T. Stirrup | A. Faleye
[1] Huldrych F. Günthard,et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel , 2018, JAMA.
[2] M. Zazzi,et al. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor , 2018, The Journal of antimicrobial chemotherapy.
[3] E. Maltezos,et al. Prevalence of drug resistance among HIV-1 treatment-naive patients in Greece during 2003-2015: Transmitted drug resistance is due to onward transmissions. , 2017, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[4] S. Little,et al. No Substantial Evidence for Sexual Transmission of Minority HIV Drug Resistance Mutations in Men Who Have Sex with Men , 2017, Journal of Virology.
[5] A. Phillips,et al. Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses , 2016, The Lancet. Public health.
[6] C. Verhofstede,et al. Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of Hypermutation , 2016, Journal of Clinical Microbiology.
[7] Jan Albert,et al. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] O. Gascuel,et al. A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK , 2015, AIDS.
[9] L. Held,et al. Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. , 2015, The Journal of infectious diseases.
[10] C. Rouzioux,et al. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies. , 2015, The Journal of antimicrobial chemotherapy.
[11] D. Pillay,et al. Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] J. Lundgren,et al. Global HIV‐1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial , 2015, HIV medicine.
[13] Jerome H. Kim,et al. Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis , 2015, PLoS medicine.
[14] M. Kozal,et al. Transmission of HIV drug resistance: lessons from sensitive screening assays , 2015, Current Opinion in Infectious Diseases.
[15] A. Wensing,et al. Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance. , 2015, The Journal of antimicrobial chemotherapy.
[16] Guangdi Li,et al. Trends and Predictors of Transmitted Drug Resistance (TDR) and Clusters with TDR in a Local Belgian HIV-1 Epidemic , 2014, PloS one.
[17] D. Webster,et al. Persistence of HIV-1 Transmitted Drug Resistance Mutations , 2013, The Journal of infectious diseases.
[18] A. Wensing,et al. Evolutionary pathways of transmitted drug-resistant HIV-1. , 2011, The Journal of antimicrobial chemotherapy.
[19] D. Katzenstein,et al. Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 , 2011, Annals of Internal Medicine.
[20] Lynne Peeples,et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. , 2009, The New England journal of medicine.
[21] Anne-Mieke Vandamme,et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update , 2009, PloS one.
[22] O. Commissioner. King's College Hospital , 1857, British medical journal.
[23] K. White,et al. Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse Transcriptase and Protease in Antiretroviral Treatment-Naïve Patients do not Affect Response to Tenofovir Disoproxil Fumarate- or Tenofovir Alafenamide-Containing Regimens. , 2017, The Journal of infectious diseases.